News Quantified

ARDX – ardelyx, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Ardelyx (ARDX) was given a new $17.00 price target by Williams Trading.

Ardelyx (ARDX) had its "outperform" rating reaffirmed by Leerink Partners.

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award [Yahoo! Finance]

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Ardelyx Touts IBSRELA's 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan [Yahoo! Finance]

-14.2%

MISS

18.6%

BEAT

16.3%

BEAT

-24.5%

MISS

Leerink Partners

Form 4 ARDELYX, INC. For: Feb 24 Filed by: RAAB MICHAEL

Form 144 ARDELYX, INC. Filed by: RAAB MICHAEL

Form 4 ARDELYX, INC. For: Feb 20 Filed by: MOTT DAVID M

Form 4 ARDELYX, INC. For: Feb 20 Filed by: Reilly Joseph James

Form 4 ARDELYX, INC. For: Feb 20 Filed by: Bishop John E

Top News Gainers

9/2 Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study 71.2%

11/25 Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements 18.2%

12/3 UPDATE 1-Ardelyx's kidney disease drug reduces elevated phosphate levels in late-stage study [Yahoo! Finance News] 16.8%

3/16 Form 4 ARDELYX, INC. For: Mar 12 Filed by: Cadoret-Manier Onaiza 13.9%

9/6 Ardelyx Inc (NASDAQ: ARDX) was given a new $15.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. 13.3%

12/4 Ardelyx launches $80M stock offering; shares down 1% after hours [Seeking Alpha] 11.5%

2/14 Form SC 13G ARDELYX, INC. Filed by: RA CAPITAL MANAGEMENT, L.P. 10.6%

9/12 Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation 9.2%

10/10 Ardelyx to Host Analyst Day in New York 8.9%

8/20 Form 4 ARDELYX, INC. For: Aug 19 Filed by: GRAMMER ELIZABETH A 8.9%

Top News Decliners

12/3 Form 8-K ARDELYX, INC. For: Dec 03 -15.8%

3/16 Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors -13.0%

2/20 Form 5 ARDELYX, INC. For: Sep 05 Filed by: Rosenbaum David P. -9.0%

3/17 Form 8-K ARDELYX, INC. For: Mar 12 -8.4%

2/24 Ardelyx Inc (NASDAQ: ARDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%

1/24 Double Your Money with This Biotech [The Motley Fool] -7.9%

9/16 Ardelyx Inc (NASDAQ: ARDX) was given a new $15.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -7.7%

2/13 Ardelyx Inc (NASDAQ: ARDX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -6.8%

10/8 Form 4 ARDELYX, INC. For: Oct 07 Filed by: Kaufmann Mark -6.4%

6/14 Form 8-K ARDELYX, INC. For: Jun 13 -6.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day